Physician profile
Rohit L Pankhaniya
NPI 1356398200
$34,272.09
in general payments reported to CMS, 2019-2025
29 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $184 · 2021: $9,478 · 2022: $7,679 · 2023: $3,968 · 2024: $740 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Food and Beverage: $2,165 · Travel and Lodging: $539 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Food and Beverage | $2,165.06 |
| Travel and Lodging | $538.53 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $29,865.04 | 2019-2024 | Auryxia |
| Glaxosmithkline, LLC. | $1,017.64 | 2022-2023 | Jesduvroq |
| Astrazeneca Pharmaceuticals Lp | $519.09 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $348.23 | 2022-2025 | |
| Amgen INC. | $309.79 | 2022-2025 | Krystexxa, Tavneos, Bkemv |
| Mallinckrodt Hospital Products INC. | $285.40 | 2023-2025 | Acthar, Terlivaz |
| Ardelyx, INC. | $277.26 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $224.40 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $219.34 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $177.70 | 2019-2020 | |
| Travere Therapeutics, INC. | $159.22 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2021 | |
| Novo Nordisk INC | $96.80 | 2023-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $90.44 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $82.37 | 2019-2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $69.06 | 2024-2025 | |
| Outset Medical INC | $67.21 | 2022 | |
| Mallinckrodt Enterprises LLC | $63.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.08 | 2023 | Jardiance |
| Baxter Healthcare | $38.48 | 2020 | |
| Fresenius USA Marketing, INC. | $36.83 | 2023-2025 | Velphoro, Korsuva |
| Alnylam Pharmaceuticals INC. | $28.13 | 2025 | Givlaari |
| Aurinia Pharma U.S., INC. | $24.91 | 2023 | Lupkynis |
| Renalytix Ai, INC. | $22.77 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $20.43 | 2023 | Jardiance |
| Genzyme Corporation | $20.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.12 | 2024 | |
| Kyowa Kirin, INC. | $18.75 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Pankhaniya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.